Spots Global Cancer Trial Database for atezolizumab
Every month we try and update this database with for atezolizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC | NCT05418660 | Non-small Cell ... | Immunotherapy | 18 Years - | University of Milano Bicocca | |
| Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer | NCT03340558 | Metastatic Colo... | Atezolizumab Cobimetinib | 18 Years - | Duke University | |
| Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | NCT05781308 | Non Small Cell ... | Paclitaxel Bevacizumab Atezolizumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | NCT04677504 | Biliary Tract C... | Atezolizumab Bevacizumab Placebo Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site | NCT05110781 | Locally Advance... Resectable Cuta... Stage III Cutan... | Atezolizumab Radiation Thera... Therapeutic Con... | 18 Years - | University of California, Davis | |
| Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | NCT03465891 | Lymphoma | atezolizumab Low- Dose, Loca... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer | NCT05797493 | Small Cell Lung... | Atezolizumab | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | NCT03946358 | Squamous Cell C... Anal Canal Canc... Cervical Cancer | Blood sample co... Tumor biopsies CT scan Atezolizumab UCPVax | 18 Years - 75 Years | Centre Hospitalier Universitaire de Besancon | |
| Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | NCT04721132 | Resectable Hepa... Stage I Hepatoc... Stage IA Hepato... Stage IB Hepato... Stage II Hepato... | Atezolizumab Bevacizumab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | NCT04776447 | Lung Diseases Carcinoma, Non-... Stage IIIA Non-... Stage IIIB Non-... Respiratory Tra... Carcinoma Bronc... Thoracic Neopla... | Carboplatin Placlitaxel Atezolizumab | 18 Years - 75 Years | Fundación GECP | |
| Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | NCT03272217 | Urothelial Carc... | Atezolizumab Bevacizumab | 18 Years - | Hoosier Cancer Research Network | |
| Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | NCT03063762 | Renal Cell Carc... | Atezolizumab Bevacizumab RO6874281 | 18 Years - | Hoffmann-La Roche | |
| A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista | NCT04487067 | Carcinoma, Hepa... | Atezolizumab Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | NCT00781612 | Neoplasm Metast... | Docetaxel Paclitaxel Pertuzumab Trastuzumab Trastuzumab Emt... Atezolizumab | 18 Years - | Genentech, Inc. | |
| SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | NCT04480372 | Malignant Pleur... Non-small Cell ... | Gemcitabine Atezolizumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | NCT04857138 | Solid Tumors | RO7300490 Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02839707 | Fallopian Tube ... Ovarian High Gr... Ovarian Seromuc... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... | Atezolizumab Bevacizumab Computed Tomogr... Pegylated Lipos... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | NCT04691817 | Lung Cancer, No... | Atezolizumab Tocilizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) | NCT03399643 | Urothelial Carc... | Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | NCT02715531 | Solid Tumor | 5-FU Atezolizumab Bevacizumab Gemcitabine Leucovorin Nab-Paclitaxel Oxaliplatin Capecitabine Cisplatin | 18 Years - | Hoffmann-La Roche | |
| Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT03708224 | Cancer Carcinoma Squamous Cell C... Head and Neck C... | Atezolizumab Tocilizumab Tiragolumab | 18 Years - | University of California, San Francisco | |
| A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | NCT03292172 | Advanced Ovaria... Triple Negative... | Atezolizumab RO6870810 | 18 Years - | Hoffmann-La Roche | |
| Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma | NCT03892525 | Recurrent B-Cel... Refractory B-Ce... | Selicrelumab Atezolizumab | 18 Years - | The Lymphoma Academic Research Organisation | |
| Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | NCT04471415 | Advanced Solid ... Non Small Cell ... | DRP-104 atezolizumab | 18 Years - | Dracen Pharmaceuticals, Inc. | |
| The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | NCT03694262 | Endometrial Can... Uterine Carcino... | Rucaparib Bevacizumab Atezolizumab | 18 Years - | Medical College of Wisconsin | |
| Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | NCT04367311 | Lung Cancer NSCLC | Atezolizumab Docetaxel Cisplatin Pemetrexed | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | NCT02541604 | Solid Tumor | Atezolizumab | - 30 Years | Hoffmann-La Roche | |
| Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | NCT04471428 | Carcinoma, Non-... | Cabozantinib Atezolizumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN | NCT04939480 | Squamous Cell C... | Atezolizumab | 18 Years - | University Hospital, Essen | |
| Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib | NCT04099836 | Non Small Cell ... | Atezolizumab Bevacizumab | 18 Years - | Duke University | |
| This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers | NCT03618953 | HPV-Associated ... | Ad-E6E7 MG1-E6E7 Atezolizumab | 18 Years - | Turnstone Biologics, Corp. | |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | NCT06287775 | Extensive Stage... Stage IV Lung C... | Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Durvalumab Echocardiograph... Iadademstat Magnetic Resona... Multigated Acqu... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | NCT03866239 | Colorectal Canc... | Obinutuzumab Atezolizumab Cibisatamab Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma | NCT03979066 | Pancreatic Duct... | Atezolizumab PEGPH20 | 18 Years - 99 Years | Columbia University | |
| A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors | NCT02350673 | Solid Tumors | Atezolizumab Cergutuzumab Am... | 18 Years - | Hoffmann-La Roche | |
| Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants | NCT04167137 | Metastatic Soli... Lymphoma | SYNB1891 Atezolizumab | 18 Years - | Synlogic | |
| A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors | NCT04440735 | Advanced Solid ... Non Small Cell ... Colorectal Canc... | DSP107 Atezolizumab | 18 Years - | Kahr Medical | |
| A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | NCT03292172 | Advanced Ovaria... Triple Negative... | Atezolizumab RO6870810 | 18 Years - | Hoffmann-La Roche | |
| Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer | NCT05425940 | Colorectal Canc... | XL092 Atezolizumab Regorafenib | 18 Years - | Exelixis | |
| A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments | NCT05152472 | Unresectable Ga... Locally Advance... Metastatic Gast... | Atezolizumab 12... Imatinib 400 MG | 18 Years - | Centre Leon Berard | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | NCT04262154 | Metastatic Pros... | Atezolizumab Abiraterone Prednisone GnRH analog Stereotactic Bo... Enzalutamide Follow up | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | NCT03818997 | Esophageal Canc... Biliary Tract C... GastroEsophagea... Hepatobiliary N... | DKN-01 Atezolizumab Paclitaxel | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | NCT03946358 | Squamous Cell C... Anal Canal Canc... Cervical Cancer | Blood sample co... Tumor biopsies CT scan Atezolizumab UCPVax | 18 Years - 75 Years | Centre Hospitalier Universitaire de Besancon | |
| EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | NCT06390059 | Metastatic Panc... | Tumor Treating ... Atezolizumab Gemcitabine nab-paclitaxel | 18 Years - | NovoCure Ltd. | |
| Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | NCT04739670 | Metastatic Trip... | Atezolizumab Bevacizumab Gemcitabine Carboplatin | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | NCT02748889 | Small Cell Lung... | Carboplatin Etoposide MPDL3280A | 18 Years - | Georgetown University | |
| A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment | NCT04338269 | Carcinoma, Rena... | Atezolizumab Cabozantinib | 18 Years - | Hoffmann-La Roche | |
| A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer | NCT04302025 | Non-small Cell ... | Alectinib Entrectinib Vemurafenib (En... Cobimetinib (En... Pralsetinib (En... Atezolizumab SBRT Resection Chemotherapy Divarasib | 18 Years - | Genentech, Inc. | |
| A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | NCT02323191 | Solid Cancers | Atezolizumab Emactuzumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients | NCT04696939 | Small-cell Lung... Neoadjuvant The... | Atezolizumab Carboplatin Etoposide | 18 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC | NCT02303951 | Malignant Melan... | Vemurafenib Cobimetinib Atezolizumab | 18 Years - | University Hospital Tuebingen | |
| A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista | NCT04487067 | Carcinoma, Hepa... | Atezolizumab Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients | NCT04696939 | Small-cell Lung... Neoadjuvant The... | Atezolizumab Carboplatin Etoposide | 18 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | NCT01903993 | Non-Small Cell ... | Docetaxel Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | NCT03125928 | HER2-positive B... | Atezolizumab Paclitaxel Trastuzumab Pertuzumab | 18 Years - | Fox Chase Cancer Center | |
| A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | NCT02951767 | Bladder Cancer | Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | NCT04677504 | Biliary Tract C... | Atezolizumab Bevacizumab Placebo Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | NCT01810913 | Oropharyngeal p... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... | Atezolizumab Biospecimen Col... Cetuximab Cisplatin Computed Tomogr... Docetaxel Intensity-Modul... Laboratory Biom... Magnetic Resona... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | NCT02705196 | Pancreatic Canc... | delolimogene mu... gemcitabine nab-paclitaxel atezolizumab | 18 Years - | Lokon Pharma AB | |
| Polish Microbiome Map | NCT04169867 | Melanoma Healthy Volunte... Microbiome Metagenome Immunotherapy | Collection of s... | 18 Years - | Ardigen | |
| A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | NCT04102618 | Breast Cancer | Pelareorep Letrozole Atezolizumab Trastuzumab | 18 Years - | Oncolytics Biotech | |
| Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | NCT04249167 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Locally Advance... Metastatic Trip... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Atezolizumab Cryosurgery Nab-paclitaxel | 18 Years - | Mayo Clinic | |
| A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | NCT03273153 | Advanced BRAFV6... | Cobimetinib Atezolizumab Pembrolizumab | 18 Years - | Hoffmann-La Roche | |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | NCT04402788 | Extensive Stage... | Atezolizumab Biospecimen Col... Computed Tomogr... Magnetic Resona... Positron Emissi... Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer | NCT04300647 | Cervical Cancer | Tiragolumab Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC | NCT03616691 | Non Small Cell ... | Atezolizumab Bevacizumab | 20 Years - | Samsung Medical Center | |
| Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma | NCT06133062 | Hepatocellular ... | Atezolizumab Bevacizumab Proton radiothe... | 18 Years - | Chang Gung Memorial Hospital | |
| Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer | NCT04869501 | Cancer | TJ004309 Atezolizumab | - | I-Mab Biopharma US Limited | |
| Montreal Immune-Related Adverse Events (MIRAE) Study | NCT05139706 | Cancer Immune System D... Inflammatory Re... Autoimmune Dise... | 18 Years - 100 Years | Sir Mortimer B. Davis - Jewish General Hospital | ||
| A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | NCT04102098 | Carcinoma, Hepa... | Atezolizumab Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | NCT03421288 | Gastric Cancer Gastroesophagea... | Atezolizumab 5-Fluorouracil Calciumfolinat Oxaliplatin Docetaxel | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | NCT04467723 | NSCLC Stage IV NSCLC, Recurren... | Atezolizumab | 18 Years - | University of Kansas Medical Center | |
| Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | NCT02807636 | Urothelial Carc... | Atezolizumab Carboplatin Gemcitabine Placebo Cisplatin | 18 Years - | Hoffmann-La Roche | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | NCT05112965 | Neoplasms | Atezolizumab Bevacizumab Pemetrexed Paclitaxel Enzalutamide | 18 Years - | Hoffmann-La Roche | |
| Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | NCT03014648 | Advanced Non-sm... | Atezolizumab | 18 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
